home.aspx
 
EVENTS

22nd Annual European Pharma Congress
22ND ANNUAL EUROPEAN PHARMA CONGRESS
May 18-19, 2020
The most anticipated Pharma event in the world and you're invited to attend 22nd   Annual European Pharma Congressscheduled during May 18-19, 2020 at Berlin, Germany which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions! This strategic conference...

Alcon

SHARESHARESHARE
Alcon, A Division of Novartis, is the global leader in eye care. Our mission is to discover new ways to enhance sight and improve people's lives. We were founded in 1945 as a small ophthalmic shop in Fort Worth, Texas. Over the past 70 years, we have become the world’s leading eye care company through a combination of innovative research and development, strategic acquisitions, and partnerships with renowned third-party organizations. Today, we proudly reach more than 90 percent of the globe – operating in more than 75 countries, serving 180 markets and employing more than 18,000 people.
SHARESHARESHARE

RELATED NEWS


Novartis has begun 2019 at a sprint, upgrading its sales forecasts for the year after strong performances from psoriasis drug Cosentyx and cardiology medicine Entresto. The company’s revolutionary CAR-T cancer cell therapy Kymriah has also begun to gain traction after a slow launch, according to the Q1 figures. Novartis has forecast a $4.7 billion windfall next quarter from the company’s decision to spin off its Alcon eye care business as part of its new focus on innovative medicines...

READ MORE

Alcon is officially a standalone company. The eye care specialist has officially spun out from Swiss pharma giant Novartis. Alcon began trading today on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.” David Endicott, Alcon’s chief executive officer, said that for more than 70 years, Alcon has been dedicated to eye care and health. Now, as a standalone company, Alcon is pursuing additional opportunities to further that mission, he said.
“W...


READ MORE

Novartis has finalized plans for the long-awaited spin-off of its Alcon eye care business, announcing that the new company will list on April 9. The Swiss pharma has approval for listing on the SIX Swiss Exchange and the New York Stock Exchange, adding that Alcon is expected to list on Switzerland’s SMI blue-chip stock index on its first trading day. Alcon will have secured debt financing of $3.5 billion, adding that Bank of America Merrill Lynch and UBS were advising Novartis on the trans...

READ MORE

Richard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of March, sparking further speculation about the unit’s future. The Swiss drugmaker said that current region head for Europe, Francesco Balestrieri, has been appointed ad-interim CEO of Sandoz, reporting to Vas Narasimhan, Novartis’ CEO. Francis gave few reasons for stepping down, save that he could not commit to a “multi-year transformation” of Sandoz for person...

READ MORE

Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients. Alcon will use its SMART digital technology suite to connect multiple diagnostic and surgical devices through a digital, open cloud-based infrastructure that integrates with clinics’ existing cataract diagnostic equipment, electronic medical record (EMR) systems, and specialist software for cataracts.
The aim is ...


READ MORE

EVENTS

22nd Annual European Pharma Congress
22ND ANNUAL EUROPEAN PHARMA CONGRESS
May 18-19, 2020
The most anticipated Pharma event in the world and you're invited to attend 22nd   Annual European Pharma Congressscheduled during May 18-19, 2020 at Berlin, Germany which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions! This strategic conference...